Neon Therapeutics Inc (NTGN) Expected to Post Earnings of -$0.79 Per Share

Share on StockTwits

Equities research analysts predict that Neon Therapeutics Inc (NASDAQ:NTGN) will report earnings per share of ($0.79) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Neon Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.75) and the lowest estimate coming in at ($0.85). The business is scheduled to announce its next earnings report on Monday, November 5th.

On average, analysts expect that Neon Therapeutics will report full-year earnings of ($5.48) per share for the current financial year, with EPS estimates ranging from ($5.61) to ($5.39). For the next year, analysts forecast that the firm will post earnings of ($3.18) per share, with EPS estimates ranging from ($3.52) to ($2.70). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Neon Therapeutics.

Neon Therapeutics (NASDAQ:NTGN) last announced its quarterly earnings data on Monday, August 6th. The company reported ($7.84) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($7.04).

Several equities analysts have recently issued reports on NTGN shares. Cann reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Neon Therapeutics in a research note on Tuesday, August 7th. Bank of America started coverage on shares of Neon Therapeutics in a report on Monday, July 23rd. They issued a “buy” rating and a $18.00 target price for the company. Oppenheimer started coverage on shares of Neon Therapeutics in a report on Monday, July 23rd. They issued a “$11.74” rating and a $20.00 target price for the company. LADENBURG THALM/SH SH started coverage on shares of Neon Therapeutics in a report on Monday, October 1st. They issued a “buy” rating and a $20.00 target price for the company. Finally, Morgan Stanley started coverage on shares of Neon Therapeutics in a report on Monday, July 23rd. They issued an “overweight” rating and a $23.00 target price for the company. Four investment analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $20.20.

Several institutional investors and hedge funds have recently made changes to their positions in the business. TRV GP Iii LLC acquired a new position in shares of Neon Therapeutics in the second quarter worth about $122,745,000. FMR LLC acquired a new position in shares of Neon Therapeutics in the second quarter worth about $26,746,000. Partner Fund Management L.P. acquired a new position in shares of Neon Therapeutics in the second quarter worth about $10,771,000. Hillhouse Capital Management Ltd. acquired a new position in shares of Neon Therapeutics in the second quarter worth about $8,969,000. Finally, Harvard Management Co. Inc. acquired a new position in shares of Neon Therapeutics in the second quarter worth about $6,374,000. Institutional investors own 65.75% of the company’s stock.

Shares of NTGN opened at $8.31 on Tuesday. Neon Therapeutics has a 12-month low of $6.17 and a 12-month high of $16.23.

About Neon Therapeutics

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Featured Article: What is the Book Value of a Share?

Get a free copy of the Zacks research report on Neon Therapeutics (NTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply